Thursday, May 19, 2011
Endo Pharmaceuticals Holdings Inc., of Chadds Ford, Pa., and Bioniche Life Sciences Inc., of Belleville, Ontario, said preliminary Phase III results from an interim analysis showed that Urocidin, its intravesical formulation of Mycobacterial cell wall-DNA complex, showed that the product was well tolerated. The overall one-year disease-free survival rate was 25 percent, breaking down to 35 percent for patients with only papillary tumors and 21 percent for patients with carcinoma in situ with or without papillary tumors. The study enrolled 129 patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.